SlideShare a Scribd company logo
European Vaccine Action Plan 
(EVAP) 
Dr Nedret Emiroglu 
Deputy Director, Division of Communicable Diseases, 
Health Security and Environment 
Special Representative of the Regional Director on 
the Millennium Development Goals and Governance
Immunization coverage for selected antigens, 
WHO European Region, 1990–2013 
100 
90 
80 
70 
60 
50 
40 
30 
20 
10 
0 
1990 
1991 
1992 
1993 
1994 
1995 
1996 
1997 
1998 
1999 
2000 
2001 
2002 
Source: WHO/United Nations Children’s Fund (UNICEF) adjusted coverage estimates. 
2003 
2004 
2005 
2006 
2007 
2008 
2009 
2010 
2011 
2012 
2013 
Coverage (% ) 
Year 
DTP3 
HepB3 
Hib3 
Pol3 
dtp3 
hepb3 
hib3 
pol3 
Legend: 3 doses of vaccines 
for diphtheria, tetanus and 
pertussis (DTP3), hepatitis 
B (HepB3), Haemophilus 
influenzae type B (Hib3) 
and poliomyelitis (Pol3).
Building on achievements 
• Political commitment 
• Addressing immunity gaps 
• Vaccine hesitancy and refusal 
• Integration with other health 
interventions 
• Alignment with changes in 
health systems 
• Sustainable access to vaccines 
and predictable funding
Europe’s response and guiding principles 
Alignment with 
regional policies
2013 2014 
EVAP timeline 
1st draft 2nd draft 
RC64 version 
RC64 
September 
2014 
Outline 
RC63 
September 
2013 
Regional consultation (face to face and web based) 
European Technical Advisory Group of Experts on Immunization (ETAGE) 
Engagement of the Standing Committee 
of the Regional Committee (SCRC)
EVAP vision
EVAP goals
EVAP objectives 
1. All countries commit to immunization 
as a priority 
2. Individuals understand the value of 
immunization services and vaccines and 
demand vaccination 
3. The benefits of immunization are equitably 
extended to all people through tailored, 
innovative strategies 
4. Strong immunization systems are an integral 
part of a well-functioning health system 
5. Immunization programmes have sustainable 
access to predictable funding and high-quality 
supply
Operationalization of EVAP 
From EVAP goals 
and objectives to 
priority action 
areas and 
proposed actions
EVAP monitoring and evaluation framework 
• Aligned with the global 
framework 
• Using existing mechanism 
and data (joint reporting 
form, with no new 
indicators or variables) 
• Secretariat to prepare 
annual progress reports 
on implementation
Draft resolution 
Regional Committee adopts EVAP 
and urges Member States: 
• to commit to immunization as a 
priority; 
• to harmonize their national 
immunization plans with EVAP; 
and 
• to provide information on the 
risks and benefits.
Draft resolution 
Requests the Regional Director: 
• to support the implementation of 
EVAP; 
• to provide leadership and call for 
resources; 
• to provide guidance in targeting 
specific high-risk groups, including 
those hesitant about vaccination; 
and 
• to monitor and evaluate progress.
Thank you

More Related Content

What's hot

Progress in and priorities for implementing the regional plans for the health...
Progress in and priorities for implementing the regional plans for the health...Progress in and priorities for implementing the regional plans for the health...
Progress in and priorities for implementing the regional plans for the health...
WHO Regional Office for Europe
 
Regional plan for implementation (RPI) of programme budget (PB) 2018–2019 in ...
Regional plan for implementation (RPI) of programme budget (PB) 2018–2019 in ...Regional plan for implementation (RPI) of programme budget (PB) 2018–2019 in ...
Regional plan for implementation (RPI) of programme budget (PB) 2018–2019 in ...
WHO Regional Office for Europe
 
Presentation - WHO Draft Global International Health Regulations (IHR)(2005) ...
Presentation - WHO Draft Global International Health Regulations (IHR)(2005) ...Presentation - WHO Draft Global International Health Regulations (IHR)(2005) ...
Presentation - WHO Draft Global International Health Regulations (IHR)(2005) ...
WHO Regional Office for Europe
 
Medical slidesharev2
Medical slidesharev2Medical slidesharev2
Medical slidesharev2
Primary Care Commissioning (PCC)
 
Rosarie lynch, EPA, HSE and ESRI, Environment, Health and Wellbeing Conferenc...
Rosarie lynch, EPA, HSE and ESRI, Environment, Health and Wellbeing Conferenc...Rosarie lynch, EPA, HSE and ESRI, Environment, Health and Wellbeing Conferenc...
Rosarie lynch, EPA, HSE and ESRI, Environment, Health and Wellbeing Conferenc...
Environmental Protection Agency, Ireland
 
Presentation –Health laboratory strengthening: Better Labs for Better Health ...
Presentation –Health laboratory strengthening: Better Labs for Better Health ...Presentation –Health laboratory strengthening: Better Labs for Better Health ...
Presentation –Health laboratory strengthening: Better Labs for Better Health ...
WHO Regional Office for Europe
 
Framework of Engagement with non-State actors (FENSA)
Framework of Engagement with non-State actors (FENSA)Framework of Engagement with non-State actors (FENSA)
Framework of Engagement with non-State actors (FENSA)
WHO Regional Office for Europe
 
GS43_8. Hold-FAST. strategy
GS43_8. Hold-FAST. strategyGS43_8. Hold-FAST. strategy
GS43_8. Hold-FAST. strategy
EuFMD
 
WHO reform: progress and implications for the European Region
WHO reform:progress and implications for the European RegionWHO reform:progress and implications for the European Region
WHO reform: progress and implications for the European Region
WHO Regional Office for Europe
 
PPT, Swedish National Audit Office, Audit of COVID related expenditures, SIG...
 PPT, Swedish National Audit Office, Audit of COVID related expenditures, SIG... PPT, Swedish National Audit Office, Audit of COVID related expenditures, SIG...
PPT, Swedish National Audit Office, Audit of COVID related expenditures, SIG...
Support for Improvement in Governance and Management SIGMA
 
Anders Wallensten: SHARP WP5 Brief Introduction – Strengthening IHR Core Capa...
Anders Wallensten: SHARP WP5 Brief Introduction – Strengthening IHR Core Capa...Anders Wallensten: SHARP WP5 Brief Introduction – Strengthening IHR Core Capa...
Anders Wallensten: SHARP WP5 Brief Introduction – Strengthening IHR Core Capa...
THL
 
Outcome document of the 2014 United Nations General Assembly high-level meet...
Outcome document of the 2014 United Nations General Assembly high-level meet...Outcome document of the 2014 United Nations General Assembly high-level meet...
Outcome document of the 2014 United Nations General Assembly high-level meet...
WHO Regional Office for Europe
 
Vaccination in WHO - European Region
Vaccination in WHO - European RegionVaccination in WHO - European Region
Vaccination in WHO - European Region
Tamar Naskidashvili
 
Health 2020 implementation, 2012–2014
Health 2020 implementation, 2012–2014Health 2020 implementation, 2012–2014
Health 2020 implementation, 2012–2014
WHO Regional Office for Europe
 
Program expenditure classification - Cristina CLASARA, Philippines
Program expenditure classification - Cristina CLASARA, PhilippinesProgram expenditure classification - Cristina CLASARA, Philippines
Program expenditure classification - Cristina CLASARA, Philippines
OECD Governance
 
Programme budgeting for health - Edwin Lau, OECD Secretariat
Programme budgeting for health - Edwin Lau, OECD SecretariatProgramme budgeting for health - Edwin Lau, OECD Secretariat
Programme budgeting for health - Edwin Lau, OECD Secretariat
OECD Governance
 
Presentation - European Vaccine Action Plan 2015–2020: opportunities and thre...
Presentation - European Vaccine Action Plan 2015–2020: opportunities and thre...Presentation - European Vaccine Action Plan 2015–2020: opportunities and thre...
Presentation - European Vaccine Action Plan 2015–2020: opportunities and thre...
WHO Regional Office for Europe
 
THE GF-TADs INITIATIVE FOR THE GLOBAL CONTROL OF AFRICAN SWINE FEVER
THE GF-TADs INITIATIVE FOR THE GLOBAL CONTROL OF AFRICAN SWINE FEVERTHE GF-TADs INITIATIVE FOR THE GLOBAL CONTROL OF AFRICAN SWINE FEVER
THE GF-TADs INITIATIVE FOR THE GLOBAL CONTROL OF AFRICAN SWINE FEVER
EuFMD
 
Daniela Jacob: Laboratory Preparedness and Responsiveness (SHARP JA WP7)
Daniela Jacob: Laboratory Preparedness and Responsiveness (SHARP JA WP7)Daniela Jacob: Laboratory Preparedness and Responsiveness (SHARP JA WP7)
Daniela Jacob: Laboratory Preparedness and Responsiveness (SHARP JA WP7)
THL
 
Holmgren redd+ monitoring and information overview 21 march 2011 final
Holmgren redd+ monitoring and information overview 21 march 2011 finalHolmgren redd+ monitoring and information overview 21 march 2011 final
Holmgren redd+ monitoring and information overview 21 march 2011 final
theREDDdesk
 

What's hot (20)

Progress in and priorities for implementing the regional plans for the health...
Progress in and priorities for implementing the regional plans for the health...Progress in and priorities for implementing the regional plans for the health...
Progress in and priorities for implementing the regional plans for the health...
 
Regional plan for implementation (RPI) of programme budget (PB) 2018–2019 in ...
Regional plan for implementation (RPI) of programme budget (PB) 2018–2019 in ...Regional plan for implementation (RPI) of programme budget (PB) 2018–2019 in ...
Regional plan for implementation (RPI) of programme budget (PB) 2018–2019 in ...
 
Presentation - WHO Draft Global International Health Regulations (IHR)(2005) ...
Presentation - WHO Draft Global International Health Regulations (IHR)(2005) ...Presentation - WHO Draft Global International Health Regulations (IHR)(2005) ...
Presentation - WHO Draft Global International Health Regulations (IHR)(2005) ...
 
Medical slidesharev2
Medical slidesharev2Medical slidesharev2
Medical slidesharev2
 
Rosarie lynch, EPA, HSE and ESRI, Environment, Health and Wellbeing Conferenc...
Rosarie lynch, EPA, HSE and ESRI, Environment, Health and Wellbeing Conferenc...Rosarie lynch, EPA, HSE and ESRI, Environment, Health and Wellbeing Conferenc...
Rosarie lynch, EPA, HSE and ESRI, Environment, Health and Wellbeing Conferenc...
 
Presentation –Health laboratory strengthening: Better Labs for Better Health ...
Presentation –Health laboratory strengthening: Better Labs for Better Health ...Presentation –Health laboratory strengthening: Better Labs for Better Health ...
Presentation –Health laboratory strengthening: Better Labs for Better Health ...
 
Framework of Engagement with non-State actors (FENSA)
Framework of Engagement with non-State actors (FENSA)Framework of Engagement with non-State actors (FENSA)
Framework of Engagement with non-State actors (FENSA)
 
GS43_8. Hold-FAST. strategy
GS43_8. Hold-FAST. strategyGS43_8. Hold-FAST. strategy
GS43_8. Hold-FAST. strategy
 
WHO reform: progress and implications for the European Region
WHO reform:progress and implications for the European RegionWHO reform:progress and implications for the European Region
WHO reform: progress and implications for the European Region
 
PPT, Swedish National Audit Office, Audit of COVID related expenditures, SIG...
 PPT, Swedish National Audit Office, Audit of COVID related expenditures, SIG... PPT, Swedish National Audit Office, Audit of COVID related expenditures, SIG...
PPT, Swedish National Audit Office, Audit of COVID related expenditures, SIG...
 
Anders Wallensten: SHARP WP5 Brief Introduction – Strengthening IHR Core Capa...
Anders Wallensten: SHARP WP5 Brief Introduction – Strengthening IHR Core Capa...Anders Wallensten: SHARP WP5 Brief Introduction – Strengthening IHR Core Capa...
Anders Wallensten: SHARP WP5 Brief Introduction – Strengthening IHR Core Capa...
 
Outcome document of the 2014 United Nations General Assembly high-level meet...
Outcome document of the 2014 United Nations General Assembly high-level meet...Outcome document of the 2014 United Nations General Assembly high-level meet...
Outcome document of the 2014 United Nations General Assembly high-level meet...
 
Vaccination in WHO - European Region
Vaccination in WHO - European RegionVaccination in WHO - European Region
Vaccination in WHO - European Region
 
Health 2020 implementation, 2012–2014
Health 2020 implementation, 2012–2014Health 2020 implementation, 2012–2014
Health 2020 implementation, 2012–2014
 
Program expenditure classification - Cristina CLASARA, Philippines
Program expenditure classification - Cristina CLASARA, PhilippinesProgram expenditure classification - Cristina CLASARA, Philippines
Program expenditure classification - Cristina CLASARA, Philippines
 
Programme budgeting for health - Edwin Lau, OECD Secretariat
Programme budgeting for health - Edwin Lau, OECD SecretariatProgramme budgeting for health - Edwin Lau, OECD Secretariat
Programme budgeting for health - Edwin Lau, OECD Secretariat
 
Presentation - European Vaccine Action Plan 2015–2020: opportunities and thre...
Presentation - European Vaccine Action Plan 2015–2020: opportunities and thre...Presentation - European Vaccine Action Plan 2015–2020: opportunities and thre...
Presentation - European Vaccine Action Plan 2015–2020: opportunities and thre...
 
THE GF-TADs INITIATIVE FOR THE GLOBAL CONTROL OF AFRICAN SWINE FEVER
THE GF-TADs INITIATIVE FOR THE GLOBAL CONTROL OF AFRICAN SWINE FEVERTHE GF-TADs INITIATIVE FOR THE GLOBAL CONTROL OF AFRICAN SWINE FEVER
THE GF-TADs INITIATIVE FOR THE GLOBAL CONTROL OF AFRICAN SWINE FEVER
 
Daniela Jacob: Laboratory Preparedness and Responsiveness (SHARP JA WP7)
Daniela Jacob: Laboratory Preparedness and Responsiveness (SHARP JA WP7)Daniela Jacob: Laboratory Preparedness and Responsiveness (SHARP JA WP7)
Daniela Jacob: Laboratory Preparedness and Responsiveness (SHARP JA WP7)
 
Holmgren redd+ monitoring and information overview 21 march 2011 final
Holmgren redd+ monitoring and information overview 21 march 2011 finalHolmgren redd+ monitoring and information overview 21 march 2011 final
Holmgren redd+ monitoring and information overview 21 march 2011 final
 

Similar to European Vaccine Action Plan (EVAP)

TOPIC 1 IMUNIZATION SYSTEMS AND OPERATIONS.pdf
TOPIC 1 IMUNIZATION SYSTEMS AND OPERATIONS.pdfTOPIC 1 IMUNIZATION SYSTEMS AND OPERATIONS.pdf
TOPIC 1 IMUNIZATION SYSTEMS AND OPERATIONS.pdf
Chisupa
 
European Commission support actions for laboratory preparedness
European Commission support actions for laboratory preparednessEuropean Commission support actions for laboratory preparedness
European Commission support actions for laboratory preparedness
European Center for Disease Prevention and Control (ECDC)
 
The National Antibiotic Guidelines: Shepherding Clinicians towards Rational u...
The National Antibiotic Guidelines: Shepherding Clinicians towards Rational u...The National Antibiotic Guidelines: Shepherding Clinicians towards Rational u...
The National Antibiotic Guidelines: Shepherding Clinicians towards Rational u...
Philippine Hospital Infection Control Society
 
Impact of hepatitis B vaccination on acute hepatitis B epidemiology in EU/EEA...
Impact of hepatitis B vaccination on acute hepatitis B epidemiology in EU/EEA...Impact of hepatitis B vaccination on acute hepatitis B epidemiology in EU/EEA...
Impact of hepatitis B vaccination on acute hepatitis B epidemiology in EU/EEA...
European Centre for Disease Prevention and Control
 
Presentation –Action plan for the health sector response to HIV
Presentation –Action plan for the health sector response to HIV Presentation –Action plan for the health sector response to HIV
Presentation –Action plan for the health sector response to HIV
WHO Regional Office for Europe
 
Slides for education_session_low_res
Slides for education_session_low_resSlides for education_session_low_res
Slides for education_session_low_res
evansrn
 
END TB 2015 strategy
END TB 2015 strategyEND TB 2015 strategy
END TB 2015 strategy
Dr.Waseemsha ShanawazBasha
 
OS16 - 5.2.a UK Experience of Modelling in Support of FMD Control, Applying...
OS16 - 5.2.a   UK Experience of Modelling in Support of FMD Control, Applying...OS16 - 5.2.a   UK Experience of Modelling in Support of FMD Control, Applying...
OS16 - 5.2.a UK Experience of Modelling in Support of FMD Control, Applying...
EuFMD
 
PROMISE ethics panel final report, October 17, 2012
PROMISE ethics panel final report, October 17, 2012PROMISE ethics panel final report, October 17, 2012
PROMISE ethics panel final report, October 17, 2012
erikanature
 
Influenza vaccine effectiveness studies in Europe - Pasi Penttinen ECDC
Influenza vaccine effectiveness studies in Europe - Pasi Penttinen ECDCInfluenza vaccine effectiveness studies in Europe - Pasi Penttinen ECDC
Influenza vaccine effectiveness studies in Europe - Pasi Penttinen ECDC
DRIVE research
 
GLOBAL STRATEGY FOR MEASLES ELIMINATION
GLOBAL STRATEGY FOR MEASLES ELIMINATIONGLOBAL STRATEGY FOR MEASLES ELIMINATION
GLOBAL STRATEGY FOR MEASLES ELIMINATION
Preetam Kar
 
Dots
DotsDots
NATIONAL IMMUNISATION PROGRAMME ...
NATIONAL IMMUNISATION PROGRAMME ...NATIONAL IMMUNISATION PROGRAMME ...
NATIONAL IMMUNISATION PROGRAMME ...
amol askar
 
Ecdc brussels may_2017
Ecdc brussels may_2017Ecdc brussels may_2017
Presentation – Action plan for the health sector response to viral hepatitis
Presentation – Action plan for the health sector response to viral hepatitis Presentation – Action plan for the health sector response to viral hepatitis
Presentation – Action plan for the health sector response to viral hepatitis
WHO Regional Office for Europe
 
SUJEET Kumar jha NVBDCP community medicine
SUJEET Kumar jha NVBDCP community medicineSUJEET Kumar jha NVBDCP community medicine
SUJEET Kumar jha NVBDCP community medicine
DrSujeetKumarJha
 
EPI Senegal comprehensive multi-year plan for 2012-2016
EPI Senegal comprehensive multi-year plan for 2012-2016 EPI Senegal comprehensive multi-year plan for 2012-2016
EPI Senegal comprehensive multi-year plan for 2012-2016
vencheles23
 
National Immunization Program of Nepal from POSDCORB Perspectives
National Immunization Program of Nepal from POSDCORB PerspectivesNational Immunization Program of Nepal from POSDCORB Perspectives
National Immunization Program of Nepal from POSDCORB Perspectives
Mohammad Aslam Shaiekh
 
WHO Guidelines on Core Components of Infection Prevention and Control (IPC) P...
WHO Guidelines on Core Components of Infection Prevention and Control (IPC) P...WHO Guidelines on Core Components of Infection Prevention and Control (IPC) P...
WHO Guidelines on Core Components of Infection Prevention and Control (IPC) P...
Philippine Hospital Infection Contol Nurses Associaton (PHICNA) Inc.
 
Massimo Ciotti: ECDC Activities in the Area of Preparedness
Massimo Ciotti: ECDC Activities in the Area of PreparednessMassimo Ciotti: ECDC Activities in the Area of Preparedness
Massimo Ciotti: ECDC Activities in the Area of Preparedness
THL
 

Similar to European Vaccine Action Plan (EVAP) (20)

TOPIC 1 IMUNIZATION SYSTEMS AND OPERATIONS.pdf
TOPIC 1 IMUNIZATION SYSTEMS AND OPERATIONS.pdfTOPIC 1 IMUNIZATION SYSTEMS AND OPERATIONS.pdf
TOPIC 1 IMUNIZATION SYSTEMS AND OPERATIONS.pdf
 
European Commission support actions for laboratory preparedness
European Commission support actions for laboratory preparednessEuropean Commission support actions for laboratory preparedness
European Commission support actions for laboratory preparedness
 
The National Antibiotic Guidelines: Shepherding Clinicians towards Rational u...
The National Antibiotic Guidelines: Shepherding Clinicians towards Rational u...The National Antibiotic Guidelines: Shepherding Clinicians towards Rational u...
The National Antibiotic Guidelines: Shepherding Clinicians towards Rational u...
 
Impact of hepatitis B vaccination on acute hepatitis B epidemiology in EU/EEA...
Impact of hepatitis B vaccination on acute hepatitis B epidemiology in EU/EEA...Impact of hepatitis B vaccination on acute hepatitis B epidemiology in EU/EEA...
Impact of hepatitis B vaccination on acute hepatitis B epidemiology in EU/EEA...
 
Presentation –Action plan for the health sector response to HIV
Presentation –Action plan for the health sector response to HIV Presentation –Action plan for the health sector response to HIV
Presentation –Action plan for the health sector response to HIV
 
Slides for education_session_low_res
Slides for education_session_low_resSlides for education_session_low_res
Slides for education_session_low_res
 
END TB 2015 strategy
END TB 2015 strategyEND TB 2015 strategy
END TB 2015 strategy
 
OS16 - 5.2.a UK Experience of Modelling in Support of FMD Control, Applying...
OS16 - 5.2.a   UK Experience of Modelling in Support of FMD Control, Applying...OS16 - 5.2.a   UK Experience of Modelling in Support of FMD Control, Applying...
OS16 - 5.2.a UK Experience of Modelling in Support of FMD Control, Applying...
 
PROMISE ethics panel final report, October 17, 2012
PROMISE ethics panel final report, October 17, 2012PROMISE ethics panel final report, October 17, 2012
PROMISE ethics panel final report, October 17, 2012
 
Influenza vaccine effectiveness studies in Europe - Pasi Penttinen ECDC
Influenza vaccine effectiveness studies in Europe - Pasi Penttinen ECDCInfluenza vaccine effectiveness studies in Europe - Pasi Penttinen ECDC
Influenza vaccine effectiveness studies in Europe - Pasi Penttinen ECDC
 
GLOBAL STRATEGY FOR MEASLES ELIMINATION
GLOBAL STRATEGY FOR MEASLES ELIMINATIONGLOBAL STRATEGY FOR MEASLES ELIMINATION
GLOBAL STRATEGY FOR MEASLES ELIMINATION
 
Dots
DotsDots
Dots
 
NATIONAL IMMUNISATION PROGRAMME ...
NATIONAL IMMUNISATION PROGRAMME ...NATIONAL IMMUNISATION PROGRAMME ...
NATIONAL IMMUNISATION PROGRAMME ...
 
Ecdc brussels may_2017
Ecdc brussels may_2017Ecdc brussels may_2017
Ecdc brussels may_2017
 
Presentation – Action plan for the health sector response to viral hepatitis
Presentation – Action plan for the health sector response to viral hepatitis Presentation – Action plan for the health sector response to viral hepatitis
Presentation – Action plan for the health sector response to viral hepatitis
 
SUJEET Kumar jha NVBDCP community medicine
SUJEET Kumar jha NVBDCP community medicineSUJEET Kumar jha NVBDCP community medicine
SUJEET Kumar jha NVBDCP community medicine
 
EPI Senegal comprehensive multi-year plan for 2012-2016
EPI Senegal comprehensive multi-year plan for 2012-2016 EPI Senegal comprehensive multi-year plan for 2012-2016
EPI Senegal comprehensive multi-year plan for 2012-2016
 
National Immunization Program of Nepal from POSDCORB Perspectives
National Immunization Program of Nepal from POSDCORB PerspectivesNational Immunization Program of Nepal from POSDCORB Perspectives
National Immunization Program of Nepal from POSDCORB Perspectives
 
WHO Guidelines on Core Components of Infection Prevention and Control (IPC) P...
WHO Guidelines on Core Components of Infection Prevention and Control (IPC) P...WHO Guidelines on Core Components of Infection Prevention and Control (IPC) P...
WHO Guidelines on Core Components of Infection Prevention and Control (IPC) P...
 
Massimo Ciotti: ECDC Activities in the Area of Preparedness
Massimo Ciotti: ECDC Activities in the Area of PreparednessMassimo Ciotti: ECDC Activities in the Area of Preparedness
Massimo Ciotti: ECDC Activities in the Area of Preparedness
 

More from WHO Regional Office for Europe

EpiData 4/2022, Ежемесячная сводка эпидемиологических данных об отдельных упр...
EpiData 4/2022, Ежемесячная сводка эпидемиологических данных об отдельных упр...EpiData 4/2022, Ежемесячная сводка эпидемиологических данных об отдельных упр...
EpiData 4/2022, Ежемесячная сводка эпидемиологических данных об отдельных упр...
WHO Regional Office for Europe
 
Measles and rubella monthly update—WHO European Region, 4/2022
Measles and rubella monthly update—WHO European Region, 4/2022Measles and rubella monthly update—WHO European Region, 4/2022
Measles and rubella monthly update—WHO European Region, 4/2022
WHO Regional Office for Europe
 
Ежемесячная сводка эпидемиологических данных ВОЗ, 3/2022
Ежемесячная сводка эпидемиологических данных ВОЗ, 3/2022Ежемесячная сводка эпидемиологических данных ВОЗ, 3/2022
Ежемесячная сводка эпидемиологических данных ВОЗ, 3/2022
WHO Regional Office for Europe
 
EpiData 3/2022, for the period March 2021—February 2022 (data as of 30 March...
EpiData 3/2022,  for the period March 2021—February 2022 (data as of 30 March...EpiData 3/2022,  for the period March 2021—February 2022 (data as of 30 March...
EpiData 3/2022, for the period March 2021—February 2022 (data as of 30 March...
WHO Regional Office for Europe
 
Epidata 3/2022
Epidata  3/2022Epidata  3/2022
Ежемесячные обновленные данные по кори и краснухе—Европейского региона ВОЗ 2/...
Ежемесячные обновленные данные по кори и краснухе—Европейского региона ВОЗ 2/...Ежемесячные обновленные данные по кори и краснухе—Европейского региона ВОЗ 2/...
Ежемесячные обновленные данные по кори и краснухе—Европейского региона ВОЗ 2/...
WHO Regional Office for Europe
 
Measles and rubella monthly update—WHO European Region 2/2022
Measles and rubella monthly update—WHO European Region 2/2022Measles and rubella monthly update—WHO European Region 2/2022
Measles and rubella monthly update—WHO European Region 2/2022
WHO Regional Office for Europe
 
EpiData 1/2022 Russian
EpiData 1/2022 RussianEpiData 1/2022 Russian
EpiData 1/2022 Russian
WHO Regional Office for Europe
 
EpiData 1/2022
EpiData 1/2022EpiData 1/2022
EpiData 12/2021 Russian
EpiData 12/2021 RussianEpiData 12/2021 Russian
EpiData 12/2021 Russian
WHO Regional Office for Europe
 
Epidata 12/2021
Epidata 12/2021Epidata 12/2021
Ежемесячная сводка Epidata Russian 11/2021
Ежемесячная сводка Epidata Russian 11/2021Ежемесячная сводка Epidata Russian 11/2021
Ежемесячная сводка Epidata Russian 11/2021
WHO Regional Office for Europe
 
Epidata 11/2021
Epidata 11/2021 Epidata 11/2021
EpiData 10/2021
EpiData 10/2021EpiData 10/2021
EpiData 9/2021 for the period September 2020—August 2021 (data as of 30 Septe...
EpiData 9/2021 for the period September 2020—August 2021 (data as of 30 Septe...EpiData 9/2021 for the period September 2020—August 2021 (data as of 30 Septe...
EpiData 9/2021 for the period September 2020—August 2021 (data as of 30 Septe...
WHO Regional Office for Europe
 
Ежемесячная сводка таблица 8/2021.
Ежемесячная сводка таблица 8/2021.Ежемесячная сводка таблица 8/2021.
Ежемесячная сводка таблица 8/2021.
WHO Regional Office for Europe
 
EpiData 8/2021
EpiData 8/2021EpiData 8/2021
EpiData 7/2021 Reported measles cases for the period July 2020—June 2021 (dat...
EpiData 7/2021 Reported measles cases for the period July 2020—June 2021 (dat...EpiData 7/2021 Reported measles cases for the period July 2020—June 2021 (dat...
EpiData 7/2021 Reported measles cases for the period July 2020—June 2021 (dat...
WHO Regional Office for Europe
 
EpiData 5/2021
EpiData 5/2021EpiData 5/2021
EpiData monthly 4/2021
EpiData monthly 4/2021EpiData monthly 4/2021
EpiData monthly 4/2021
WHO Regional Office for Europe
 

More from WHO Regional Office for Europe (20)

EpiData 4/2022, Ежемесячная сводка эпидемиологических данных об отдельных упр...
EpiData 4/2022, Ежемесячная сводка эпидемиологических данных об отдельных упр...EpiData 4/2022, Ежемесячная сводка эпидемиологических данных об отдельных упр...
EpiData 4/2022, Ежемесячная сводка эпидемиологических данных об отдельных упр...
 
Measles and rubella monthly update—WHO European Region, 4/2022
Measles and rubella monthly update—WHO European Region, 4/2022Measles and rubella monthly update—WHO European Region, 4/2022
Measles and rubella monthly update—WHO European Region, 4/2022
 
Ежемесячная сводка эпидемиологических данных ВОЗ, 3/2022
Ежемесячная сводка эпидемиологических данных ВОЗ, 3/2022Ежемесячная сводка эпидемиологических данных ВОЗ, 3/2022
Ежемесячная сводка эпидемиологических данных ВОЗ, 3/2022
 
EpiData 3/2022, for the period March 2021—February 2022 (data as of 30 March...
EpiData 3/2022,  for the period March 2021—February 2022 (data as of 30 March...EpiData 3/2022,  for the period March 2021—February 2022 (data as of 30 March...
EpiData 3/2022, for the period March 2021—February 2022 (data as of 30 March...
 
Epidata 3/2022
Epidata  3/2022Epidata  3/2022
Epidata 3/2022
 
Ежемесячные обновленные данные по кори и краснухе—Европейского региона ВОЗ 2/...
Ежемесячные обновленные данные по кори и краснухе—Европейского региона ВОЗ 2/...Ежемесячные обновленные данные по кори и краснухе—Европейского региона ВОЗ 2/...
Ежемесячные обновленные данные по кори и краснухе—Европейского региона ВОЗ 2/...
 
Measles and rubella monthly update—WHO European Region 2/2022
Measles and rubella monthly update—WHO European Region 2/2022Measles and rubella monthly update—WHO European Region 2/2022
Measles and rubella monthly update—WHO European Region 2/2022
 
EpiData 1/2022 Russian
EpiData 1/2022 RussianEpiData 1/2022 Russian
EpiData 1/2022 Russian
 
EpiData 1/2022
EpiData 1/2022EpiData 1/2022
EpiData 1/2022
 
EpiData 12/2021 Russian
EpiData 12/2021 RussianEpiData 12/2021 Russian
EpiData 12/2021 Russian
 
Epidata 12/2021
Epidata 12/2021Epidata 12/2021
Epidata 12/2021
 
Ежемесячная сводка Epidata Russian 11/2021
Ежемесячная сводка Epidata Russian 11/2021Ежемесячная сводка Epidata Russian 11/2021
Ежемесячная сводка Epidata Russian 11/2021
 
Epidata 11/2021
Epidata 11/2021 Epidata 11/2021
Epidata 11/2021
 
EpiData 10/2021
EpiData 10/2021EpiData 10/2021
EpiData 10/2021
 
EpiData 9/2021 for the period September 2020—August 2021 (data as of 30 Septe...
EpiData 9/2021 for the period September 2020—August 2021 (data as of 30 Septe...EpiData 9/2021 for the period September 2020—August 2021 (data as of 30 Septe...
EpiData 9/2021 for the period September 2020—August 2021 (data as of 30 Septe...
 
Ежемесячная сводка таблица 8/2021.
Ежемесячная сводка таблица 8/2021.Ежемесячная сводка таблица 8/2021.
Ежемесячная сводка таблица 8/2021.
 
EpiData 8/2021
EpiData 8/2021EpiData 8/2021
EpiData 8/2021
 
EpiData 7/2021 Reported measles cases for the period July 2020—June 2021 (dat...
EpiData 7/2021 Reported measles cases for the period July 2020—June 2021 (dat...EpiData 7/2021 Reported measles cases for the period July 2020—June 2021 (dat...
EpiData 7/2021 Reported measles cases for the period July 2020—June 2021 (dat...
 
EpiData 5/2021
EpiData 5/2021EpiData 5/2021
EpiData 5/2021
 
EpiData monthly 4/2021
EpiData monthly 4/2021EpiData monthly 4/2021
EpiData monthly 4/2021
 

Recently uploaded

CHEMOTHERAPY_RDP_CHAPTER 3_ANTIFUNGAL AGENT.pdf
CHEMOTHERAPY_RDP_CHAPTER 3_ANTIFUNGAL AGENT.pdfCHEMOTHERAPY_RDP_CHAPTER 3_ANTIFUNGAL AGENT.pdf
CHEMOTHERAPY_RDP_CHAPTER 3_ANTIFUNGAL AGENT.pdf
rishi2789
 
Cardiac Assessment for B.sc Nursing Student.pdf
Cardiac Assessment for B.sc Nursing Student.pdfCardiac Assessment for B.sc Nursing Student.pdf
Cardiac Assessment for B.sc Nursing Student.pdf
shivalingatalekar1
 
Ketone bodies and metabolism-biochemistry
Ketone bodies and metabolism-biochemistryKetone bodies and metabolism-biochemistry
Ketone bodies and metabolism-biochemistry
Dhayanithi C
 
June 2024 Oncology Cartoons By Dr Kanhu Charan Patro
June 2024 Oncology Cartoons By Dr Kanhu Charan PatroJune 2024 Oncology Cartoons By Dr Kanhu Charan Patro
June 2024 Oncology Cartoons By Dr Kanhu Charan Patro
Kanhu Charan
 
Top Travel Vaccinations in Manchester
Top Travel Vaccinations in ManchesterTop Travel Vaccinations in Manchester
Top Travel Vaccinations in Manchester
NX Healthcare
 
Efficacy of Avartana Sneha in Ayurveda
Efficacy of Avartana Sneha in AyurvedaEfficacy of Avartana Sneha in Ayurveda
Efficacy of Avartana Sneha in Ayurveda
Dr. Jyothirmai Paindla
 
REGULATION FOR COMBINATION PRODUCTS AND MEDICAL DEVICES.pptx
REGULATION FOR COMBINATION PRODUCTS AND MEDICAL DEVICES.pptxREGULATION FOR COMBINATION PRODUCTS AND MEDICAL DEVICES.pptx
REGULATION FOR COMBINATION PRODUCTS AND MEDICAL DEVICES.pptx
LaniyaNasrink
 
Demystifying Fallopian Tube Blockage- Grading the Differences and Implication...
Demystifying Fallopian Tube Blockage- Grading the Differences and Implication...Demystifying Fallopian Tube Blockage- Grading the Differences and Implication...
Demystifying Fallopian Tube Blockage- Grading the Differences and Implication...
FFragrant
 
Cervical Disc Arthroplasty ORSI 2024.pptx
Cervical Disc Arthroplasty ORSI 2024.pptxCervical Disc Arthroplasty ORSI 2024.pptx
Cervical Disc Arthroplasty ORSI 2024.pptx
LEFLOT Jean-Louis
 
Tests for analysis of different pharmaceutical.pptx
Tests for analysis of different pharmaceutical.pptxTests for analysis of different pharmaceutical.pptx
Tests for analysis of different pharmaceutical.pptx
taiba qazi
 
CHEMOTHERAPY_RDP_CHAPTER 1_ANTI TB DRUGS.pdf
CHEMOTHERAPY_RDP_CHAPTER 1_ANTI TB DRUGS.pdfCHEMOTHERAPY_RDP_CHAPTER 1_ANTI TB DRUGS.pdf
CHEMOTHERAPY_RDP_CHAPTER 1_ANTI TB DRUGS.pdf
rishi2789
 
10 Benefits an EPCR Software should Bring to EMS Organizations
10 Benefits an EPCR Software should Bring to EMS Organizations   10 Benefits an EPCR Software should Bring to EMS Organizations
10 Benefits an EPCR Software should Bring to EMS Organizations
Traumasoft LLC
 
K CỔ TỬ CUNG.pdf tự ghi chép, chữ hơi xấu
K CỔ TỬ CUNG.pdf tự ghi chép, chữ hơi xấuK CỔ TỬ CUNG.pdf tự ghi chép, chữ hơi xấu
K CỔ TỬ CUNG.pdf tự ghi chép, chữ hơi xấu
HongBiThi1
 
Hemodialysis: Chapter 5, Dialyzers Overview - Dr.Gawad
Hemodialysis: Chapter 5, Dialyzers Overview - Dr.GawadHemodialysis: Chapter 5, Dialyzers Overview - Dr.Gawad
Hemodialysis: Chapter 5, Dialyzers Overview - Dr.Gawad
NephroTube - Dr.Gawad
 
Medical Quiz ( Online Quiz for API Meet 2024 ).pdf
Medical Quiz ( Online Quiz for API Meet 2024 ).pdfMedical Quiz ( Online Quiz for API Meet 2024 ).pdf
Medical Quiz ( Online Quiz for API Meet 2024 ).pdf
Jim Jacob Roy
 
vonoprazan A novel drug for GERD presentation
vonoprazan A novel drug for GERD presentationvonoprazan A novel drug for GERD presentation
vonoprazan A novel drug for GERD presentation
Dr.pavithra Anandan
 
DECLARATION OF HELSINKI - History and principles
DECLARATION OF HELSINKI - History and principlesDECLARATION OF HELSINKI - History and principles
DECLARATION OF HELSINKI - History and principles
anaghabharat01
 
share - Lions, tigers, AI and health misinformation, oh my!.pptx
share - Lions, tigers, AI and health misinformation, oh my!.pptxshare - Lions, tigers, AI and health misinformation, oh my!.pptx
share - Lions, tigers, AI and health misinformation, oh my!.pptx
Tina Purnat
 
CHEMOTHERAPY_RDP_CHAPTER 4_ANTI VIRAL DRUGS.pdf
CHEMOTHERAPY_RDP_CHAPTER 4_ANTI VIRAL DRUGS.pdfCHEMOTHERAPY_RDP_CHAPTER 4_ANTI VIRAL DRUGS.pdf
CHEMOTHERAPY_RDP_CHAPTER 4_ANTI VIRAL DRUGS.pdf
rishi2789
 
Chapter 11 Nutrition and Chronic Diseases.pptx
Chapter 11 Nutrition and Chronic Diseases.pptxChapter 11 Nutrition and Chronic Diseases.pptx
Chapter 11 Nutrition and Chronic Diseases.pptx
Earlene McNair
 

Recently uploaded (20)

CHEMOTHERAPY_RDP_CHAPTER 3_ANTIFUNGAL AGENT.pdf
CHEMOTHERAPY_RDP_CHAPTER 3_ANTIFUNGAL AGENT.pdfCHEMOTHERAPY_RDP_CHAPTER 3_ANTIFUNGAL AGENT.pdf
CHEMOTHERAPY_RDP_CHAPTER 3_ANTIFUNGAL AGENT.pdf
 
Cardiac Assessment for B.sc Nursing Student.pdf
Cardiac Assessment for B.sc Nursing Student.pdfCardiac Assessment for B.sc Nursing Student.pdf
Cardiac Assessment for B.sc Nursing Student.pdf
 
Ketone bodies and metabolism-biochemistry
Ketone bodies and metabolism-biochemistryKetone bodies and metabolism-biochemistry
Ketone bodies and metabolism-biochemistry
 
June 2024 Oncology Cartoons By Dr Kanhu Charan Patro
June 2024 Oncology Cartoons By Dr Kanhu Charan PatroJune 2024 Oncology Cartoons By Dr Kanhu Charan Patro
June 2024 Oncology Cartoons By Dr Kanhu Charan Patro
 
Top Travel Vaccinations in Manchester
Top Travel Vaccinations in ManchesterTop Travel Vaccinations in Manchester
Top Travel Vaccinations in Manchester
 
Efficacy of Avartana Sneha in Ayurveda
Efficacy of Avartana Sneha in AyurvedaEfficacy of Avartana Sneha in Ayurveda
Efficacy of Avartana Sneha in Ayurveda
 
REGULATION FOR COMBINATION PRODUCTS AND MEDICAL DEVICES.pptx
REGULATION FOR COMBINATION PRODUCTS AND MEDICAL DEVICES.pptxREGULATION FOR COMBINATION PRODUCTS AND MEDICAL DEVICES.pptx
REGULATION FOR COMBINATION PRODUCTS AND MEDICAL DEVICES.pptx
 
Demystifying Fallopian Tube Blockage- Grading the Differences and Implication...
Demystifying Fallopian Tube Blockage- Grading the Differences and Implication...Demystifying Fallopian Tube Blockage- Grading the Differences and Implication...
Demystifying Fallopian Tube Blockage- Grading the Differences and Implication...
 
Cervical Disc Arthroplasty ORSI 2024.pptx
Cervical Disc Arthroplasty ORSI 2024.pptxCervical Disc Arthroplasty ORSI 2024.pptx
Cervical Disc Arthroplasty ORSI 2024.pptx
 
Tests for analysis of different pharmaceutical.pptx
Tests for analysis of different pharmaceutical.pptxTests for analysis of different pharmaceutical.pptx
Tests for analysis of different pharmaceutical.pptx
 
CHEMOTHERAPY_RDP_CHAPTER 1_ANTI TB DRUGS.pdf
CHEMOTHERAPY_RDP_CHAPTER 1_ANTI TB DRUGS.pdfCHEMOTHERAPY_RDP_CHAPTER 1_ANTI TB DRUGS.pdf
CHEMOTHERAPY_RDP_CHAPTER 1_ANTI TB DRUGS.pdf
 
10 Benefits an EPCR Software should Bring to EMS Organizations
10 Benefits an EPCR Software should Bring to EMS Organizations   10 Benefits an EPCR Software should Bring to EMS Organizations
10 Benefits an EPCR Software should Bring to EMS Organizations
 
K CỔ TỬ CUNG.pdf tự ghi chép, chữ hơi xấu
K CỔ TỬ CUNG.pdf tự ghi chép, chữ hơi xấuK CỔ TỬ CUNG.pdf tự ghi chép, chữ hơi xấu
K CỔ TỬ CUNG.pdf tự ghi chép, chữ hơi xấu
 
Hemodialysis: Chapter 5, Dialyzers Overview - Dr.Gawad
Hemodialysis: Chapter 5, Dialyzers Overview - Dr.GawadHemodialysis: Chapter 5, Dialyzers Overview - Dr.Gawad
Hemodialysis: Chapter 5, Dialyzers Overview - Dr.Gawad
 
Medical Quiz ( Online Quiz for API Meet 2024 ).pdf
Medical Quiz ( Online Quiz for API Meet 2024 ).pdfMedical Quiz ( Online Quiz for API Meet 2024 ).pdf
Medical Quiz ( Online Quiz for API Meet 2024 ).pdf
 
vonoprazan A novel drug for GERD presentation
vonoprazan A novel drug for GERD presentationvonoprazan A novel drug for GERD presentation
vonoprazan A novel drug for GERD presentation
 
DECLARATION OF HELSINKI - History and principles
DECLARATION OF HELSINKI - History and principlesDECLARATION OF HELSINKI - History and principles
DECLARATION OF HELSINKI - History and principles
 
share - Lions, tigers, AI and health misinformation, oh my!.pptx
share - Lions, tigers, AI and health misinformation, oh my!.pptxshare - Lions, tigers, AI and health misinformation, oh my!.pptx
share - Lions, tigers, AI and health misinformation, oh my!.pptx
 
CHEMOTHERAPY_RDP_CHAPTER 4_ANTI VIRAL DRUGS.pdf
CHEMOTHERAPY_RDP_CHAPTER 4_ANTI VIRAL DRUGS.pdfCHEMOTHERAPY_RDP_CHAPTER 4_ANTI VIRAL DRUGS.pdf
CHEMOTHERAPY_RDP_CHAPTER 4_ANTI VIRAL DRUGS.pdf
 
Chapter 11 Nutrition and Chronic Diseases.pptx
Chapter 11 Nutrition and Chronic Diseases.pptxChapter 11 Nutrition and Chronic Diseases.pptx
Chapter 11 Nutrition and Chronic Diseases.pptx
 

European Vaccine Action Plan (EVAP)

  • 1. European Vaccine Action Plan (EVAP) Dr Nedret Emiroglu Deputy Director, Division of Communicable Diseases, Health Security and Environment Special Representative of the Regional Director on the Millennium Development Goals and Governance
  • 2. Immunization coverage for selected antigens, WHO European Region, 1990–2013 100 90 80 70 60 50 40 30 20 10 0 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 Source: WHO/United Nations Children’s Fund (UNICEF) adjusted coverage estimates. 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 Coverage (% ) Year DTP3 HepB3 Hib3 Pol3 dtp3 hepb3 hib3 pol3 Legend: 3 doses of vaccines for diphtheria, tetanus and pertussis (DTP3), hepatitis B (HepB3), Haemophilus influenzae type B (Hib3) and poliomyelitis (Pol3).
  • 3. Building on achievements • Political commitment • Addressing immunity gaps • Vaccine hesitancy and refusal • Integration with other health interventions • Alignment with changes in health systems • Sustainable access to vaccines and predictable funding
  • 4. Europe’s response and guiding principles Alignment with regional policies
  • 5. 2013 2014 EVAP timeline 1st draft 2nd draft RC64 version RC64 September 2014 Outline RC63 September 2013 Regional consultation (face to face and web based) European Technical Advisory Group of Experts on Immunization (ETAGE) Engagement of the Standing Committee of the Regional Committee (SCRC)
  • 8. EVAP objectives 1. All countries commit to immunization as a priority 2. Individuals understand the value of immunization services and vaccines and demand vaccination 3. The benefits of immunization are equitably extended to all people through tailored, innovative strategies 4. Strong immunization systems are an integral part of a well-functioning health system 5. Immunization programmes have sustainable access to predictable funding and high-quality supply
  • 9. Operationalization of EVAP From EVAP goals and objectives to priority action areas and proposed actions
  • 10. EVAP monitoring and evaluation framework • Aligned with the global framework • Using existing mechanism and data (joint reporting form, with no new indicators or variables) • Secretariat to prepare annual progress reports on implementation
  • 11. Draft resolution Regional Committee adopts EVAP and urges Member States: • to commit to immunization as a priority; • to harmonize their national immunization plans with EVAP; and • to provide information on the risks and benefits.
  • 12. Draft resolution Requests the Regional Director: • to support the implementation of EVAP; • to provide leadership and call for resources; • to provide guidance in targeting specific high-risk groups, including those hesitant about vaccination; and • to monitor and evaluate progress.